Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
Assuming approval and dependent upon the label in Europe, Novartis’ Mayzent should be well positioned for strong adoption in active secondary progressive multiple sclerosis and transitioning relapsing-remitting multiple sclerosis, although low unaided awareness of the latter patient type may hamper uptake without a focused educational strategy, according to the prelaunch assessment in a new report […]
US Gastroenterologists Project Near-Term Growth of Takeda’s Entyvio and Janssen’s Stelara for the Treatment of Crohn’s Disease, while Anticipated Increased Adoption of Pfizer’s Xeljanz in Ulcerative Colitis is Likely to Interrupt Entyvio’s Trajectory
According to a recent report by Spherix Global Insights, US gastroenterologists’ (n=99) adoption of Xeljanz for the treatment of ulcerative colitis continues to be positive, but looming safety concerns could spell trouble for the first-in-class JAK inhibitor. Download Report Overview EXTON, Pa., March. 26, 2019 /PRNewswire/ — At approximately eight months post-launch, Pfizer’s Xeljanz is continuing […]
US Rheumatologists Show Continued Uptake of Eli Lilly’s Olumiant for the Treatment of Rheumatoid Arthritis, Though Safety Concerns and Lack of Experience in the Market Withhold Full Potential
According to a recent report by Spherix Global Insights, Eli Lilly’s Olumiant and Regeneron’s Kevzara enjoy continued uptake, though rising safety concerns associated with the JAK inhibitor class may blunt Olumiant’s trajectory Download Report Overview EXTON, Pa., March. 25, 2019 /PRNewswire/ — Overall brand share among biologic/JAK-treated patients in the US rheumatoid arthritis (RA) market has […]
Spherix Global Insights’ Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva’s Ajovy Early Launch Success
Ajovy’s lack of an autoinjector may not be an obstacle for the brand as neurologists and migraine specialists report a sizeable percentage of patients treated with Amgen/Novartis’ Aimovig and Eli Lilly’s Emgality choosing to use the prefilled syringe option over the heavily promoted Aimovig SureClick and Emgality Pen devices. Download Report Overview EXTON, Pa., March 25, […]
DMT Choice for Your MS Is Your Decision
From: Multiple Sclerosis News Today By: Ed Tobias
Two Years After Launch of Genentech’s Ocrevus, US Neurologists Report a Significant and Persistent Increase in the Treatment of Patients with Primary Progressive Multiple Sclerosis
According to a new report from Spherix Global Insights, Novartis’ Mayzent is anticipated to grow the size of the secondary progressive multiple sclerosis segment in the United States, decreasing the influence of the relapsing remitting multiple sclerosis segment on market dynamics Download Report Overview EXTON, Pa., March 12, 2019 ―Expanding adoption of Genentech’s Ocrevus among […]
While Janssen’s Tremfya and Sun Pharmaceutical’s Ilumya are Enjoying Continued Uptake, AbbVie’s Skyrizi (Risankizumab) is Shaping up to be a Major Disruptor to the US Psoriasis Market if Approved
Janssen’s ECLIPSE clinical trial data demonstrating sustained response of Tremfya in comparison to Novartis’ Cosentyx will have an impact on US dermatologists’ prescribing behavior, according to a recent study by Spherix Global Insights Download Report Overview EXTON, Pa., March 11, 2019 /PRNewswire/ —Spherix Global Insights’ 12th wave of RealTime Dynamix™: Psoriasis (US), which includes the feedback of 100 […]
Overall Use of Sanofi/Regeneron’s Dupixent for the Treatment of Atopic Dermatitis in the EU5 Lags that of the US, Though Side Effects and Short-Term Use in Both Markets May be Cause for Concern
Two reports recently published by Spherix Global Insights highlight key differences and similarities in the treatment of atopic dermatitis based on recent surveys of 364 US and EU5 dermatologists EXTON, Pa., February 27, 2019/PRNewswire/ — In the latest quarterly wave of RealTime Dynamix™: Atopic Dermatitis (US) published last week, US dermatologists (n=102) report continued uptake of […]
Spherix Global Insights’ Initial Report on the European Psoriasis Market Reveals Swift Uptake of Biosimilar Use at the Expense of AbbVie’s Humira
The recent launches of adalimumab biosimilars in the EU5 (France, Italy, Germany, Spain, and the UK) have resulted in a decrease in share for name brand Humira, while newly launched products such as Janssen’s Tremfya, UCB’s Cimzia, and Almirall’s Ilumetri are having a tougher time gaining traction. Download Report Overview EXTON, Pa., February 19, 2019 […]
RealTime Dynamix™: Bone and Mineral Metabolism US Q1 2019 Spotlight
RealTime Dynamix™: Bone and Mineral Metabolism US Q1 2019 Spotlight https://www.spherixglobalinsights.com/wp-content/uploads/2019/06/rtd-bone-q1-2019.pngDownload Report Spotlight Last month Spherix surveyed 201 US nephrologists about their management of secondary hyperparathyroidism, vitamin D insufficiency, and hyperphosphatemia in the dialysis and non-dialysis settings. See complimentary highlights from the Q2 2018 wave of RealTime Dynamix™: Bone and Mineral Metabolism US below. Contact […]
